PL211018B1 - Krystaliczny związek laktamowy, kompozycja farmaceutyczna i sposób wytwarzania krystalicznego związku laktamowego - Google Patents

Krystaliczny związek laktamowy, kompozycja farmaceutyczna i sposób wytwarzania krystalicznego związku laktamowego

Info

Publication number
PL211018B1
PL211018B1 PL360991A PL36099101A PL211018B1 PL 211018 B1 PL211018 B1 PL 211018B1 PL 360991 A PL360991 A PL 360991A PL 36099101 A PL36099101 A PL 36099101A PL 211018 B1 PL211018 B1 PL 211018B1
Authority
PL
Poland
Prior art keywords
methyl
amino
benzazepin
tetrahydro
formula
Prior art date
Application number
PL360991A
Other languages
English (en)
Polish (pl)
Other versions
PL360991A1 (en
Inventor
Thomas Mitchell Koenig
James Edmund Audia
David Mitchell
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
Gary Lowell Engel
James Abraham Aikins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL360991A1 publication Critical patent/PL360991A1/xx
Publication of PL211018B1 publication Critical patent/PL211018B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
PL360991A 2000-11-17 2001-11-02 Krystaliczny związek laktamowy, kompozycja farmaceutyczna i sposób wytwarzania krystalicznego związku laktamowego PL211018B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (2)

Publication Number Publication Date
PL360991A1 PL360991A1 (en) 2004-09-20
PL211018B1 true PL211018B1 (pl) 2012-03-30

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
PL360991A PL211018B1 (pl) 2000-11-17 2001-11-02 Krystaliczny związek laktamowy, kompozycja farmaceutyczna i sposób wytwarzania krystalicznego związku laktamowego

Country Status (33)

Country Link
US (1) US20040248878A1 (enExample)
EP (1) EP1353910B1 (enExample)
JP (1) JP4116431B2 (enExample)
KR (1) KR20030045194A (enExample)
CN (2) CN101624372A (enExample)
AR (1) AR031356A1 (enExample)
AT (1) ATE362919T1 (enExample)
AU (2) AU2002224321B2 (enExample)
BR (1) BR0115424A (enExample)
CA (1) CA2425497C (enExample)
CY (1) CY1106682T1 (enExample)
CZ (1) CZ20031340A3 (enExample)
DE (1) DE60128587T2 (enExample)
DK (1) DK1353910T3 (enExample)
DZ (1) DZ3454A1 (enExample)
EA (1) EA006919B1 (enExample)
EC (1) ECSP034598A (enExample)
ES (1) ES2286162T3 (enExample)
HR (1) HRP20030385A2 (enExample)
HU (1) HUP0301862A3 (enExample)
IL (1) IL155275A0 (enExample)
MX (1) MXPA03004250A (enExample)
MY (1) MY141607A (enExample)
NO (1) NO325217B1 (enExample)
PE (1) PE20020798A1 (enExample)
PL (1) PL211018B1 (enExample)
PT (1) PT1353910E (enExample)
SK (1) SK287794B6 (enExample)
SV (1) SV2003000741A (enExample)
TW (1) TWI235151B (enExample)
UA (1) UA77165C2 (enExample)
WO (1) WO2002040451A2 (enExample)
ZA (1) ZA200303411B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
ES2413705T3 (es) 2005-04-08 2013-07-17 Daiichi Sankyo Company, Limited Derivado de piridilmetilsulfona
JP5198877B2 (ja) 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション ベンゾアゼピノン類の製造方法
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
AU2021244215A1 (en) 2020-03-26 2022-10-13 Seagen Inc. Methods of treating multiple myeloma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901343T2 (xx) * 1996-12-23 1999-09-21 Elan Pharmaceuticals, Inc. Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
EP1230220A1 (en) * 1999-11-09 2002-08-14 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis

Also Published As

Publication number Publication date
NO20032215D0 (no) 2003-05-15
SV2003000741A (es) 2003-01-13
JP4116431B2 (ja) 2008-07-09
ECSP034598A (es) 2003-06-25
WO2002040451A3 (en) 2003-08-28
HRP20030385A2 (en) 2003-08-31
PE20020798A1 (es) 2002-09-06
DK1353910T3 (da) 2007-09-10
ZA200303411B (en) 2004-08-02
KR20030045194A (ko) 2003-06-09
EA200300579A1 (ru) 2003-12-25
HUP0301862A2 (hu) 2003-09-29
NO20032215L (no) 2003-07-16
CN100516047C (zh) 2009-07-22
TWI235151B (en) 2005-07-01
US20040248878A1 (en) 2004-12-09
JP2004521084A (ja) 2004-07-15
UA77165C2 (en) 2006-11-15
DE60128587T2 (de) 2008-01-31
MY141607A (en) 2010-05-31
AU2002224321B2 (en) 2006-10-19
NO325217B1 (no) 2008-02-25
SK287794B6 (sk) 2011-10-04
ATE362919T1 (de) 2007-06-15
CA2425497A1 (en) 2002-05-23
CA2425497C (en) 2010-08-17
CN1575282A (zh) 2005-02-02
EA006919B1 (ru) 2006-04-28
CZ20031340A3 (cs) 2004-06-16
AR031356A1 (es) 2003-09-17
WO2002040451A2 (en) 2002-05-23
EP1353910A2 (en) 2003-10-22
CN101624372A (zh) 2010-01-13
SK5432003A3 (en) 2004-09-08
MXPA03004250A (es) 2003-09-22
DE60128587D1 (de) 2007-07-05
PT1353910E (pt) 2007-08-20
BR0115424A (pt) 2003-10-21
PL360991A1 (en) 2004-09-20
EP1353910B1 (en) 2007-05-23
AU2432102A (en) 2002-05-27
CY1106682T1 (el) 2012-05-23
IL155275A0 (en) 2003-11-23
DZ3454A1 (fr) 2002-05-23
ES2286162T3 (es) 2007-12-01
HUP0301862A3 (en) 2007-09-28

Similar Documents

Publication Publication Date Title
PL212199B1 (pl) Związek N-(((S)-2-hydroksy-3-metylobutyrylo)-1-(L-alaninylo))-(S)-1-amino-3-metylo-2,3,4,5-tetrahydro-1H-3-benzoazepin-2-on oraz kompozycja zawierająca ten związek
CA2425497C (en) (n)-((s)-2-hydroxy-3-methyl-butyryl-1-(l-alaninyl)-(s)-1-amino-3-methyl-2,3,4,5-tetrahydro-1h-3-benzazepin-2-one dihydrate and its use in the treatment of alzheimer's disease
AU2002224321A1 (en) Lactam compound
JP2004521084A5 (enExample)
US7468365B2 (en) Lactam compound
CA2425558C (en) Lactam compound
US20040077627A1 (en) Lactam compound
NZ525365A (en) Lactam compound
US6946459B2 (en) Crystalline forms of 1s-[1alpha(2s*,3r*), 9alpha]6, 10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9[[(1-isoquinolyl) carbonyl]amino]octahydro-6h-piridazino[1,2-a][1,2]diazepin-1-carboxamide
HK1059731B (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis

Legal Events

Date Code Title Description
RECP Rectifications of patent specification